Primecap Management CO Sage Therapeutics, Inc. Transaction History

Primecap Management CO

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	SELL	$17.1 - $22.26 $254,790 - $331,674	-14,900 Reduced 16.58%	74,950 $1.62 Million
Q3 2023 Nov 13, 2023	BUY	$16.75 - $48.98 $439,687 - $1.29 Million	26,250 Added 41.27%	89,850 $1.85 Million
Q2 2023 Aug 11, 2023	SELL	$40.65 - $59.54 $113,820 - $166,712	-2,800 Reduced 4.22%	63,600 $2.99 Million
Q1 2023 May 15, 2023	BUY	$37.27 - $46.57 $67,086 - $83,826	1,800 Added 2.79%	66,400 $2.79 Million
Q4 2022 Feb 13, 2023	SELL	$32.2 - $43.61 $425,040 - $575,652	-13,200 Reduced 16.97%	64,600 $2.46 Million
Q2 2022 Aug 11, 2022	BUY	$27.52 - $37.99 $247,680 - $341,910	9,000 Added 13.08%	77,800 $2.51 Million
Q1 2022 May 11, 2022	BUY	$30.71 - $45.71 $144,337 - $214,837	4,700 Added 7.33%	68,800 $2.28 Million
Q4 2021 Feb 11, 2022	BUY	$37.06 - $47.11 $2.38 Million - $3.02 Million	64,100 New	64,100 $2.73 Million

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $326M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Primecap Management CO, based on Form 13F filings with the SEC.

Stay updated on Primecap Management CO with notifications on news.